Ensysce Biosciences, Inc.
ENSC
$0.47
$0.000.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 27.72% | -28.50% | 25.78% | -115.13% | 10.91% |
| Total Depreciation and Amortization | 0.00% | 0.00% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,394.07% | -97.33% | 347.92% | -60.74% | 353.79% |
| Change in Net Operating Assets | -225.61% | -95.32% | -55.04% | 244.03% | -770.08% |
| Cash from Operations | 43.94% | -129.45% | 18.24% | 31.06% | -58.54% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 39.14% | -162.50% | -65.98% | 48.94% |
| Issuance of Common Stock | -- | -- | -54.28% | 3,389.28% | -97.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -7,148.15% | -100.29% | 1,391.75% |
| Cash from Financing | 3,063.54% | -101.53% | 186.81% | -22.21% | 48.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.07% | -235.18% | 589.80% | 35.97% | -87.03% |